May 18, 2020
PANTHERx® Rare Pharmacy Selected by Deciphera Pharmaceuticals to Distribute QINLOCK(TM) (ripretinib), for Gastrointestinal Stromal Tumor (GIST) Patients
May 07, 2020
Ascentage Pharma's Core Drug Candidate HQP1351 Granted Fast Track Designation by the US FDA, Marking Another Milestone in Its Development
May 04, 2020
Ascentage Pharma's Core Drug Candidate HQP1351 Granted Orphan Drug Designation by the US FDA for the Treatment of Patients with Chronic Myeloid Leukemia
Jan 09, 2020
Blueprint Medicines Announces FDA Approval of AYVAKIT(TM) (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor
Aug 07, 2019
Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
Jul 21, 2019
Ascentage Pharma to Initiate Phase Ib Study of HQP1351 in Tyrosine Kinase Inhibitors -resistant Chronic Myeloid Leukemia Patients in the US
Jun 14, 2019
Blueprint Medicines Submits New Drug Application to U.S. Food and Drug Administration for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
Jun 01, 2019
Blueprint Medicines Presents NAVIGATOR Trial Data in PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST at ASCO 2019 Supporting Planned Marketing Applications for Avapritinib
Apr 08, 2019
Armas Pharmaceuticals Expands Generic Portfolio with Launches of Capecitabine and Imatinib
Mar 04, 2019
Breckenridge Announces Final Approval of its ANDA for Imatinib Mesylate Tablets (RLD: Gleevec®)
Oct 29, 2018
Novartis wins esteemed Prix Galien Foundation Best Biotechnology Product Award for CAR-T cell therapy, Kymriah®
Jul 24, 2018
China Imatinib Market Report 2018-2022: Basic Concepts, Sales, Major Manufacturers, Prices & Market Prospects
Jun 21, 2018
Blueprint Medicines Initiates VOYAGER Phase 3 Clinical Trial of Avapritinib in Patients with Advanced Gastrointestinal Stromal Tumors
Jun 02, 2018
New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy
Mar 28, 2018
Tasigna Lawsuits Mount, as Plaintiff in Washington State Accuses Novartis of Failing to Warn that Leukemia Drug Had Been Linked to Atherosclerosis-Related Conditions, Bernstein Liebhard LLP Reports
Mar 22, 2018
Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia
Feb 16, 2018
Global Chronic Myeloid Leukemia (CML) Market Report 2017: Focus on Forecasts, Treatment, Epidemiology, Marketed Drugs & Pipeline
Dec 22, 2017
FDA updates the label of Tasigna to reflect that certain patients with a type of leukemia may be eligible to stop treatment after sustained response
Dec 19, 2017
Avillion Announces US Approval of Pfizer's BOSULIF® (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML)
Dec 10, 2017
Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity